Intracardiac Injection of Erythropoietin Induces Stem Cell Recruitment and Improves Cardiac Functions in a Rat Myocardial Infarction Model

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2009 May 19

PMID 19449462

Citations 20

Authors

Christian Klopsch

Dario Furlani

Ralf Gabel

Wenzhong Li

Erik Pittermann

Murat Ugurlucan

Guenther Kundt

Christiana Zingler

Ulf Titze

Weiwei Wang

Lee-Lee Ong

Klaus Wagner

Ren-Ke Li

Nan Ma

Gustav Steinhoff

Affiliations

Soon will be listed here.

Abstract

Erythropoietin (EPO) protects the myocardium from ischaemic injury and promotes beneficial remodelling. We assessed the therapeutic efficacy of intracardiac EPO injection and EPO-mediated stem cell homing in a rat myocardial infarction (MI) model. Following MI, EPO (3000 U/kg) or saline was delivered by intracardiac injection. Compared to myocardial infarction control group (MIC), EPO significantly improved left ventricular function (n =11-14, P < 0.05) and decreased right ventricular wall stress (n = 8, P < 0.05) assessed by pressure-volume loops after 6 weeks. MI-EPO hearts exhibited smaller infarction size (20.1 +/- 1.1% versus 27.8 +/- 1.2%; n = 6-8, P < 0.001) and greater capillary density (338.5 +/- 14.7 versus 259.8 +/- 9.2 vessels per mm2; n = 6-8, P < 0.001) than MIC hearts. Direct EPO injection reduced post-MI myocardial apoptosis by approximately 41% (0.27 +/- 0.03% versus 0.42 +/- 0.03%; n = 6, P= 0.005). The chemoattractant SDF-1 was up-regulated significantly assessed by quantitative realtime PCR and immunohistology. c-Kit(+) and CD34(+) stem cells were significantly more numerous in MI-EPO than in MIC at 24 hrs in peripheral blood (n = 7, P < 0.05) and 48 hrs in the infarcted hearts (n = 6, P < 0.001). Further, the mRNAs of Akt, eNOS and EPO receptor were significantly enhanced in MI-EPO hearts (n = 7, P < 0.05). Intracardiac EPO injection restores myocardial functions following MI, which may attribute to the improved early recruitment of c-Kit(+) and CD34(+) stem cells via the enhanced expression of chemoattractant SDF-1.

Citing Articles

The treatment of chronic anemia in heart failure: a global approach.

Bianchi V, von Haehling S Clin Res Cardiol. 2023; 113(8):1117-1136.

PMID: 37660308 DOI: 10.1007/s00392-023-02275-4.

Cardioprotective effects of erythropoietin in diabetic rats determined by CD34 and vascular endothelial growth factor levels.

Oztas Y, Meric M, Beyaz M, Onalan M, Sonmez K, Oter K Arch Med Sci Atheroscler Dis. 2021; 5:e1-e12.

PMID: 33585719 PMC: 7863553. DOI: 10.5114/amsad.2020.92346.

Promoting Cardiac Regeneration and Repair Using Acellular Biomaterials.

Vasanthan V, Hassanabad A, Pattar S, Niklewski P, Wagner K, Fedak P Front Bioeng Biotechnol. 2020; 8:291.

PMID: 32363184 PMC: 7180212. DOI: 10.3389/fbioe.2020.00291.

Intramyocardial angiogenetic stem cells and epicardial erythropoietin save the acute ischemic heart.

Klopsch C, Skorska A, Ludwig M, Lemcke H, Maass G, Gaebel R Dis Model Mech. 2018; 11(6).

PMID: 29752300 PMC: 6031356. DOI: 10.1242/dmm.033282.

Associations of high altitude polycythemia with polymorphisms in and in Chinese Han and Tibetan populations.

Liu L, Zhang Y, Zhang Z, Zhao Y, Fan X, Ma L Oncotarget. 2017; 8(32):53234-53243.

PMID: 28881807 PMC: 5581106. DOI: 10.18632/oncotarget.18384.

References

Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L . Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000; 343(16):1139-47. DOI: 10.1056/NEJM200010193431602. View

Hessel M, Steendijk P, den Adel B, Schutte C, van der Laarse A . Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol. 2006; 291(5):H2424-30. DOI: 10.1152/ajpheart.00369.2006. View

Jelkmann W, Wagner K . Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol. 2004; 83(11):673-86. DOI: 10.1007/s00277-004-0911-6. View

Jaffredo T, Nottingham W, Liddiard K, Bollerot K, Pouget C, de Bruijn M . From hemangioblast to hematopoietic stem cell: an endothelial connection?. Exp Hematol. 2005; 33(9):1029-40. DOI: 10.1016/j.exphem.2005.06.005. View

Losordo D, Schatz R, White C, Udelson J, Veereshwarayya V, Durgin M . Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation. 2007; 115(25):3165-72. DOI: 10.1161/CIRCULATIONAHA.106.687376. View

Bahlmann F, Groot K, Spandau J, Landry A, Hertel B, Duckert T . Erythropoietin regulates endothelial progenitor cells. Blood. 2003; 103(3):921-6. DOI: 10.1182/blood-2003-04-1284. View

Beltrami A, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S . Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114(6):763-76. DOI: 10.1016/s0092-8674(03)00687-1. View

Kaminski A, Ma N, Donndorf P, Lindenblatt N, Feldmeier G, Ong L . Endothelial NOS is required for SDF-1alpha/CXCR4-mediated peripheral endothelial adhesion of c-kit+ bone marrow stem cells. Lab Invest. 2007; 88(1):58-69. DOI: 10.1038/labinvest.3700693. View

Prunier F, Pfister O, Hadri L, Liang L, Monte F, Liao R . Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 2006; 292(1):H522-9. DOI: 10.1152/ajpheart.00357.2006. View

10.

Vandervelde S, Van Luyn M, Tio R, Harmsen M . Signaling factors in stem cell-mediated repair of infarcted myocardium. J Mol Cell Cardiol. 2005; 39(2):363-76. DOI: 10.1016/j.yjmcc.2005.05.012. View

11.

Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M . Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006; 48(1):176-84. DOI: 10.1016/j.jacc.2006.04.008. View

12.

Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M . Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5(4):434-8. DOI: 10.1038/7434. View

13.

Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q . Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res. 2006; 72(1):51-9. DOI: 10.1016/j.cardiores.2006.06.026. View

14.

Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Iwasa M . Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res. 2008; 79(4):611-20. DOI: 10.1093/cvr/cvn154. View

15.

Kawamoto A, Iwasaki H, Kusano K, Murayama T, Oyamada A, Silver M . CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation. 2006; 114(20):2163-9. DOI: 10.1161/CIRCULATIONAHA.106.644518. View

16.

Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S . Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci. 2006; 101(1):31-9. DOI: 10.1254/jphs.fp0050966. View

17.

Parsa C, Matsumoto A, Kim J, Riel R, Pascal L, Walton G . A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003; 112(7):999-1007. PMC: 198525. DOI: 10.1172/JCI18200. View

18.

Zwezdaryk K, Coffelt S, Figueroa Y, Liu J, Phinney D, Lamarca H . Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. Exp Hematol. 2007; 35(4):640-52. DOI: 10.1016/j.exphem.2007.01.044. View

19.

Lipsic E, van der Meer P, Henning R, Suurmeijer A, Boddeus K, Van Veldhuisen D . Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004; 44(4):473-9. DOI: 10.1097/01.fjc.0000140209.04675.c3. View

20.

Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P . Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003; 100(8):4802-6. PMC: 153636. DOI: 10.1073/pnas.0630444100. View